Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.
Three patients with B-prolymphocytic variant of HCL (HCL-V) were treated with a chlorinated purine analogue, 2-chlorodeoxyadenosine, at a daily dosage of 0.12 mg/kg in 2-hour intravenous infusion for 5 consecutive days. Partial remission was achieved in only 1 patient, who relapsed after 6 months. Two other patients did not respond to the treatment. HCL-V is a distinct clinicopathological entity which seems to be resistant to various therapeutic modalities. However, further observations are necessary in order to establish the efficacy of 2-CdA in the treatment of HCL-V.
Blasińska-Morawiec
M
M
Department of Hematology, Medical University of Lódz, Poland.
Robak
T
T
Krykowski
E
E
Hellmann
A
A
Urbańska-Ryś
H
H
D000368:Aged; D000954:Antigens, Surface / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D013154:Spleen / Q000473:pathology; D016896:Treatment Outcome
D000954:Antigens, Surface; D000970:Antineoplastic Agents; D017338:Cladribine